related documents
- A phase IIA clinical trial to evaluate a reversible Bruton's tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Conferences
- Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27 Conferences
- Atezolizumab plus bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database. Conferences
- Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC) Conferences
- Incidence of venous thromboembolism in newly diagnosed glioblastoma multi-forme and associated risk factors: A retrospective chart review Conferences
- Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach Conferences
- Practice patterns of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world Canadian practice. Conferences
- Preclinical characterization of HBW-012-E, a novel, potent, selective, safe, and orally active KRAS G12D inhibitor with superior pharmacokinetic (PK) properties and anti-tumor efficacy Conferences
- Predictors of short-term death and long-term survival in advanced hepatocellular carcinoma (HCC) treated with contemporary tyrosine kinase inhibitors (TKI) or immunotherapy: A multicenter analysis from the HCC-CHORD consortium Conferences
- Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada. Conferences
- Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial Conferences
- Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC) Conferences